中國生物製藥(01177.HK):正大天晴與安源醫藥簽訂許可和轉讓協議
格隆匯4月25日丨中國生物製藥(01177.HK)發佈公吿,公司附屬公司正大天晴與安源醫藥科技(上海)有限公司(“安源醫藥”)簽訂了就治療非酒精性脂肪性肝炎(NASH)和II型糖尿病(T2DM)的新型生物藥AP025和AP026 在中國和部分亞洲區域的開發和商業化權益的獨家許可和轉讓協議。目前,AP025已經在國內開展I 期臨牀,AP026在國外已開展I期臨牀、在國內計劃於2022年申報IND(新藥研究申請)。
公吿表示,獨家許可和轉讓協議的簽訂,可藉助安源醫藥自主創新研發的CHO生產細胞株高效開發平台、高親和力抗體創制平台、超長效蛋白設計平台及PACE特異性雙抗技術平台等技術和產品,為中國患者研好藥、做好藥,並利用正大天晴強大的工藝、臨牀開發和商業化能力以及在中國肝病和糖尿病領域的市場優勢,快速推進臨牀,惠及廣大的中國患者。同時,此次合作也為雙方未來繼續圍繞安源醫藥管線中代謝領域的產品進一步深化合作奠定了良好基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.